165 related articles for article (PubMed ID: 29020868)
1. Extended pelvic lymph-node dissection and radiotherapy with curative intent in high-risk lymph-node-positive prostate cancer: a possible curative strategy?
Al-Amiri B; Lundin F; Waldén M
Scand J Urol; 2018 Apr; 52(2):101-107. PubMed ID: 29020868
[TBL] [Abstract][Full Text] [Related]
2. Biochemical recurrence after robot-assisted extended pelvic lymphadenectomy for prostate cancer.
Chenam A; Ruel N; Pal S; Barlog J; Lau C; Wilson T; Yuh B
Can J Urol; 2018 Jun; 25(3):9340-9348. PubMed ID: 29900823
[TBL] [Abstract][Full Text] [Related]
3. Standardized comparison of robot-assisted limited and extended pelvic lymphadenectomy for prostate cancer.
Yuh BE; Ruel NH; Mejia R; Novara G; Wilson TG
BJU Int; 2013 Jul; 112(1):81-8. PubMed ID: 23351148
[TBL] [Abstract][Full Text] [Related]
4. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
[TBL] [Abstract][Full Text] [Related]
5. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
6. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
[TBL] [Abstract][Full Text] [Related]
7. Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience.
Boeri L; Sharma V; Kwon E; Stish BJ; Davis BJ; Karnes RJ
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):514-523. PubMed ID: 33268854
[TBL] [Abstract][Full Text] [Related]
8. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of immediate androgen deprivation adjuvant therapy in patients with lymph node positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy].
Miyamae K; Kitani K; Miyamoto K; Hamada S; Kawano T; Maehara A; Otsuka Y; Otsuka T; Hamada Y
Nihon Hinyokika Gakkai Zasshi; 2009 Jul; 100(5):570-5. PubMed ID: 19663244
[TBL] [Abstract][Full Text] [Related]
10. Whole pelvis radiotherapy for pathological node-positive prostate cancer : Oncological outcome and prognostic factors.
Poelaert F; Fonteyne V; Ost P; De Troyer B; Decaestecker K; De Meerleer G; De Visschere P; Claeys T; Dhondt B; Lumen N
Strahlenther Onkol; 2017 Jun; 193(6):444-451. PubMed ID: 28101585
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit.
Gupta M; Patel HD; Schwen ZR; Tran PT; Partin AW
BJU Int; 2019 Feb; 123(2):252-260. PubMed ID: 29626845
[TBL] [Abstract][Full Text] [Related]
12. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature.
Gakis G; Boorjian SA; Briganti A; Joniau S; Karazanashvili G; Karnes RJ; Mattei A; Shariat SF; Stenzl A; Wirth M; Stief CG
Eur Urol; 2014 Aug; 66(2):191-9. PubMed ID: 23735200
[TBL] [Abstract][Full Text] [Related]
13. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.
Zelefsky MJ; Gomez DR; Polkinghorn WR; Pei X; Kollmeier M
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):529-33. PubMed ID: 23523323
[TBL] [Abstract][Full Text] [Related]
14. The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer.
Jegadeesh N; Liu Y; Zhang C; Zhong J; Cassidy RJ; Gillespie T; Kucuk O; Rossi P; Master VA; Alemozaffar M; Jani AB
Cancer; 2017 Feb; 123(3):512-520. PubMed ID: 27859018
[TBL] [Abstract][Full Text] [Related]
15. More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer.
Abdollah F; Gandaglia G; Suardi N; Capitanio U; Salonia A; Nini A; Moschini M; Sun M; Karakiewicz PI; Shariat SF; Montorsi F; Briganti A
Eur Urol; 2015 Feb; 67(2):212-9. PubMed ID: 24882672
[TBL] [Abstract][Full Text] [Related]
16. Sentinel Lymph Node Dissection to Select Clinically Node-negative Prostate Cancer Patients for Pelvic Radiation Therapy: Effect on Biochemical Recurrence and Systemic Progression.
Grivas N; Wit E; Pos F; de Jong J; Vegt E; Bex A; Hendricksen K; Horenblas S; KleinJan G; van Rhijn B; van der Poel H
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):347-354. PubMed ID: 28068243
[TBL] [Abstract][Full Text] [Related]
17. Salvage pelvic lymph node dissection in recurrent prostate cancer: surgical and early oncological outcome.
Claeys T; Van Praet C; Lumen N; Ost P; Fonteyne V; De Meerleer G; Lambert B; Delrue L; De Visschere P; Villeirs G; Decaestecker K
Biomed Res Int; 2015; 2015():198543. PubMed ID: 25695051
[TBL] [Abstract][Full Text] [Related]
18. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
19. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
[TBL] [Abstract][Full Text] [Related]
20. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]